SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

OGN

Organon & Co.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-177445
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine governance filing. Monitor the company's next 10-Q for any changes in financial guidance or operational updates.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
OGN ▲ +2.77% at T+60d
NEUTRAL call +2.77% · α vs SPY -1.73% · entry $13.16 → $13.52
Entry = T+0 close
Apr 24, 2026
via day close
T+1d
+1.22%
call +1.22% · α +1.70%
$13.32
settled 6mo ago
T+5d
+0.76%
call +0.76% · α +0.36%
$13.26
settled 6mo ago
T+20d
+1.94%
call +1.94% · α -3.02%
$13.41
settled 5mo ago
T+60d
+2.77%
call +2.77% · α -1.73%
$13.52
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Organon & Co. filed a definitive proxy statement for its 2026 annual meeting, seeking shareholder approval for the election of 10 directors, executive compensation, an amendment to its stock plan, and the ratification of its auditor. The filing is routine and reflects standard corporate governance procedures.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for Organon & Co.'s 2026 annual meeting.
  • Shareholders are asked to vote on four proposals: the election of 10 directors, approval of executive compensation, an amendment to the 2021 Incentive Stock Plan, and the ratification of PricewaterhouseCoopers as the independent auditor.
  • The board of directors recommends voting 'For' on all proposals.
  • The meeting will be held virtually on June 9, 2026.

Financial Impact

The filing does not contain new financial data or material changes to the company's financial structure.

Risk Factors

  • A shareholder vote against executive compensation (say on pay) could signal governance concerns, but the board's unanimous 'For' recommendation makes this unlikely.
  • Failure to ratify the auditor would be a significant negative event, but this is also highly improbable.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177445
Document: 0001193125-26-177445-index-headers.html0001193125-26-177445
Document: 0001193125-26-177445-index.html0001193125-26-177445
Document: 0001193125-26-177445.txt0001193125-26-177445
15 reports for OGN
Performance horizon
75% Hit rate @ T+60 6 of 8 directional calls Went positive at some point 6 of 9 best @ T+60▲ +2.84%Jun 1, 2026
Filters
Rows
Reports for OGN — sortable, filterable
TypeNow
Aug 18, 2026
10w ago
Institutional Cluster
BEARISH ★ 6/10
$13.68awaiting T+60—$13.77 (−0.62%)
Jul 31, 2026
12w ago
8-K
BEARISH ★ 5/10
$13.55 $13.74▼ −1.40%▲ +1.05%$13.77 (−1.59%)
Jul 17, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$13.49 $13.77▲ +2.08%▼ −2.76%$13.77 (+2.04%)
Jun 17, 2026
18w ago
DEFM14A
BULLISH ★ 7/10
$13.42 $13.64▲ +1.64%▼ −1.51%$13.77 (+2.57%)
Jun 11, 2026
19w ago
DEFA14A
NEUTRAL ★ 3/10
$13.45 $13.78▲ +2.45%▼ −1.94%$13.77 (+2.34%)
Jun 1, 2026
21w ago
PREM14A
BULLISH ★ 8/10
$13.37 $13.75▲ +2.84%▲ +1.87%$13.77 (+2.99%)
Apr 30, 2026
25w ago
DEFA14A
NEUTRAL ★ 3/10
$13.25 $13.52▲ +2.08%▼ −0.74%$13.77 (+3.93%)
Apr 30, 2026
25w ago
8-K
BEARISH ★ 6/10
$13.25 $13.52▼ −2.08%▲ +0.74%$13.77 (−3.93%)
Apr 27, 2026
26w ago
DEFA14A
BULLISH ★ 7/10
$13.32 $13.56▲ +1.84%▼ −1.88%$13.77 (+3.38%)
Apr 27, 2026
26w ago
DEFA14A
NEUTRAL ★ 5/10
$13.32 $13.56▲ +1.84%▼ −1.88%$13.77 (+3.38%)
Showing 10 of 15

US Market Status

Market Open — Closes in 5h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026